T2952
Tetrabenazine
≥98% (HPLC), VMAT inhibitor, solid
동의어(들):
9,10-Dimethoxy-1,3,4,6,7,11b-hexahydro-3-isobutyl-(rel 3R,11bR)-2H-benzo[a]quinolizin-2-one
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C19H27NO3
CAS 번호:
Molecular Weight:
317.42
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
200-383-6
MDL number:
Beilstein/REAXYS Number:
40090
제품 이름
Tetrabenazine, ≥98% (HPLC), solid
InChI
1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1
SMILES string
COc1cc2CCN3C[C@@H](CC(C)C)C(=O)CC3c2cc1OC
InChI key
MKJIEFSOBYUXJB-GDBMZVCRSA-N
assay
≥98% (HPLC)
form
solid
solubility
DMSO: >10 mg/mL, H2O: insoluble
originator
Roche
storage temp.
2-8°C
Quality Level
유사한 제품을 찾으십니까? 방문 제품 비교 안내
Application
Tetrabenazine has been used for dopamine uptake assays in mouse brain cells1. Tetrabenazine has also been used for non-specific binding assays in postnuclear supernatants derived from PC-12 and CV-1 cells2.
Biochem/physiol Actions
Tetrabenazine is a reversible type 2 vesicular monoamine transporter (VMAT) inhibitor.
Tetrabenazine is a reversible type 2 vesicular monoamine transporter (VMAT) inhibitor. It depletes dopamine stores.
Features and Benefits
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Preparation Note
Tetrabenazine is soluble in DMSO at a concentration that is greater than 10 mg/ml and is insoluble in water.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Mahabuba Jahan et al.
EJNMMI research, 1(1), 33-33 (2012-01-05)
Fluorine-18 dihydrotetrabenazine [DTBZ] analogues, which selectively target the vesicular monoamine transporter 2 [VMAT2], have been extensively studied for in vivo quantification of beta cell mass by positron-emission tomography [PET]. This study describes a novel deuterated radioligand [18F]fluoroethyl [FE]-DTBZ-d4, aimed to
Sinéad M Murphy et al.
Annals of neurology, 72(4), 481-490 (2012-10-31)
Since the introduction of the Orphan Drug Act in 1983, designed to promote development of treatments for rare diseases, at least 378 orphan drugs have been approved. Incentives include financial support, tax credits, and perhaps most importantly, extended market exclusivity.
Marc D Normandin et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 53(6), 908-916 (2012-05-11)
The ability to noninvasively measure endogenous pancreatic β-cell mass (BCM) would accelerate research on the pathophysiology of diabetes and revolutionize the preclinical development of new treatments, the clinical assessment of therapeutic efficacy, and the early diagnosis and subsequent monitoring of
Vikas Kotagal et al.
Neurology, 82(17), 1514-1520 (2014-04-01)
Cardiovascular comorbidities associate with neurodegeneration in the elderly and may contribute to extranigral pathologies and medically refractory axial motor features in Parkinson disease (PD). We explored differences in the estimated rate of axial motor feature accrual between patients with PD
Nicolaas I Bohnen et al.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 32(8), 1609-1617 (2012-05-10)
Parkinson's disease (PD) is a multisystem neurodegenerative disorder. Heterogeneous clinical features may reflect heterogeneous changes in different brain regions. In contrast to the pronounced nigrostriatal denervation characteristic of PD, cholinergic changes are less marked. We investigated cholinergic innervation activity in
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.